NCT05944861

Brief Summary

The primary purpose of this study is to investigate the effect of the application of sacroiliac joint injection guided by combination of ultrasonography and fluoroscopy on the duration of the procedure and the amount of radiation exposed during the procedure, compared to the application of only fluoroscopy-guided technique. Secondary objectives are to evaluate the effectiveness of the treatment with both methods and to record the adverse events that may be encountered during the procedure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2023

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

March 15, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 13, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2024

Completed
Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

11 months

First QC Date

March 15, 2023

Last Update Submit

March 9, 2026

Conditions

Keywords

Sacroiliac joint painSacroiliac joint injectionUltrasonography guided injectionFlouroscopy guided injection

Outcome Measures

Primary Outcomes (1)

  • Processing Time

    The processing time will be measured by the other researcher in the processing room with the help of a stopwatch. The stopwatch will be started when the needle touches the patient and will be stopped when the procedure is finished. It will be recorded in seconds

    during the intervention

Secondary Outcomes (4)

  • Fluoroscopy Time

    during the intervention

  • Kerma-area Product (μGy)

    during the intervention

  • Visual Analogue Scale

    baseline, change from baseline VAS at 1 month after intervention

  • Oswestry Low Back Pain Disability Questionnaire

    baseline, change from baseline VAS at 1 month after intervention

Study Arms (2)

Combined ultrasonography and flouroscopy guided injeciton

EXPERIMENTAL

In 19 patients selected after randomization, the procedure will first be started with ultrasound and then continued with fluoroscopy.

Other: Combined ultrasonography and flouroscopy guided injeciton

Flouroscopy guided injection

ACTIVE COMPARATOR

In 19 patients selected after randomization, the procedure will be performed only through fluoroscopy.

Other: Flouroscopy guided injection

Interventions

In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.

Combined ultrasonography and flouroscopy guided injeciton

In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.

Flouroscopy guided injection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Low back and/or gluteal pain and/or groin pain without radicular extension below the L4 level for more than 3 months
  • Pain score greater than 3 according to NRS
  • Unresponsiveness to conservative treatment (such as exercise, NSAID)
  • At least 3 of the five sacroiliac provocation tests (FABER (Patrick), thigh thrust, Gaenslen, sacroiliac compression, and sacroiliac distraction tests) are positive

You may not qualify if:

  • Refusing to participate in the study
  • Pregnancy
  • Infective sacroiliitis
  • Malignancy
  • Osteoporosis
  • Mechanical lumbosacral pathologies (spondylolisthesis, scoliosis, stenosis, etc.)
  • Neurological finding in the lower extremity
  • Pain spreading below the knee
  • History of spinal surgery
  • History of allergy to drugs to be injected (local anesthetic, contrast material, steroid allergy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Ankara, Cankaya, 06800, Turkey (Türkiye)

Location

Study Officials

  • Serdar KESIKBURUN, MD

    SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

March 15, 2023

First Posted

July 13, 2023

Study Start

February 15, 2023

Primary Completion

January 15, 2024

Study Completion

February 15, 2024

Last Updated

March 11, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations